BAT: The Opposite of Conventional Wisdom Could the flat-out opposite of conventional wisdom prove to be effective against metastatic prostate cancer? Androgen deprivation therapy (ADT) has been the bedrock of treatment for advanced prostate cancer for more than half a century. But investigators at Johns Hopkins are rethinking it – in a way that sounds […]
Prostate MRI’s ability to show what’s happening in the prostate is already transforming how prostate biopsies are done. Will it change treatment for prostate cancer, as well? Radiologist Peter Choyke, M.D., believes it will. He is Senior Investigator and Director of the National Cancer Institute’s Molecular Imaging Branch, and I recently interviewed him for the […]
Can MRI really make a difference in diagnosing prostate cancer? Just ask Rob Gray. It took nine years for his cancer to be diagnosed. He felt like a human pincushion after going through numerous tests, exams, and five prostate biopsies – some of them saturation biopsies (each involving 20 or more needle samples!). Doctors couldn’t […]
Prostate MRI is on the upswing in cancer diagnosis. Should it play a role in screening, too? Many men with suspected prostate cancer are getting MRI, because the information it provides is so good: MRI can show the size and location of tumors and guide a personalized, targeted biopsy aimed at suspicious areas – […]
This new form of treatment for metastatic prostate cancer is being used in Europe, Australia and elsewhere, and being tested in clinical trials in the U.S. As part of my series on PSMA-targeting, here’s more of the story: We have talked a lot about the amazing results in some men with metastatic prostate cancer of […]
This new form of treatment for metastatic prostate cancer is being used in Europe, Australia and elsewhere, and being tested in clinical trials in the U.S. As part of my series on PSMA-targeting, here’s more of the story: With the dramatic results in some men, why aren’t radionuclides a done deal here in the U.S? […]
This new form of treatment for metastatic prostate cancer is being used in Europe, Australia and elsewhere, and being tested in clinical trials in the U.S. As part of my series on PSMA-targeting, here’s more of the story: As we have discussed here, Neil Bander, M.D., Director of Urological Oncology Research at Weill Cornell and […]